Drugs in Dev.
Dermatology
IND Enabling
Switzerland 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : NM26-2198
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Kaken Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
